Katrina K. Bakken

In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

J. Sarkaria, P. Decker, Minjee Kim, 2021, Molecular Cancer Therapeutics.

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

R. Verhaak, J. Sarkaria, F. Boakye-Agyeman, 2015, Journal of the National Cancer Institute.

Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

J. Sarkaria, F. Boakye-Agyeman, J. Reid, 2014, Clinical Cancer Research.

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

J. Sarkaria, B. Ma, J. Eckel-Passow, 2015, Clinical Cancer Research.

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

J. Sarkaria, P. Decker, Ying Feng, 2017, Molecular Cancer Therapeutics.

Preclinical modeling in GBM PDX xenografts to guide clinical development of lisavanbulin - a novel tumor checkpoint controller targeting microtubules.

J. Sarkaria, H. Lane, J. Eckel-Passow, 2021, Neuro-oncology.